clonidine has been researched along with Parkinsonian Disorders in 7 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was aimed at comparing the diagnostic accuracy of the growth hormone (GH) response to clonidine, arginine and both combined in order to establish a more reliable test to differentiate parkinsonism type multiple system atrophy (MSA-p) from Parkinson's disease (PD)." | 9.14 | The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease. ( Fu, Y; Song, C; Wan, Q; Zeng, Y; Zhang, K, 2010) |
| " Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity." | 7.74 | Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008) |
| "This study was aimed at comparing the diagnostic accuracy of the growth hormone (GH) response to clonidine, arginine and both combined in order to establish a more reliable test to differentiate parkinsonism type multiple system atrophy (MSA-p) from Parkinson's disease (PD)." | 5.14 | The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease. ( Fu, Y; Song, C; Wan, Q; Zeng, Y; Zhang, K, 2010) |
| " Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity." | 3.74 | Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008) |
| " Chronic administration of low doses of the neurotoxin 1-methy,4-phenyl,1,2,3,6-tetrahydropyridine (MPTP) can induce cognitive dysfunction in non-human primates, including impaired performance on a variable delayed response (VDR) task with attentional and memory components." | 1.36 | Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism. ( Decamp, E; Schneider, JS; Tinker, JP, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ostock, CY | 1 |
| Hallmark, J | 1 |
| Palumbo, N | 1 |
| Bhide, N | 1 |
| Conti, M | 1 |
| George, JA | 1 |
| Bishop, C | 1 |
| Tanabe, M | 1 |
| Hashimoto, M | 1 |
| Ono, H | 1 |
| Schneider, JS | 1 |
| Tinker, JP | 1 |
| Decamp, E | 1 |
| Zhang, K | 1 |
| Zeng, Y | 1 |
| Song, C | 1 |
| Fu, Y | 1 |
| Wan, Q | 1 |
| de Rooij, SE | 1 |
| Jansen, PA | 1 |
| Samson, MM | 1 |
| Verhaar, HJ | 1 |
| Moons, CG | 1 |
| Archer, T | 1 |
| Fredriksson, A | 1 |
| Nash, JR | 1 |
| Wilson, SJ | 1 |
| Potokar, JP | 1 |
| Nutt, DJ | 1 |
1 trial available for clonidine and Parkinsonian Disorders
| Article | Year |
|---|---|
The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease.
Topics: Aged; Arginine; Clonidine; Diagnosis, Differential; Drug Combinations; Female; Human Growth Hormone; | 2010 |
6 other studies available for clonidine and Parkinsonian Disorders
| Article | Year |
|---|---|
Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Antiparkinso | 2015 |
Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzazepines | 2008 |
Clonidine improves attentional and memory components of delayed response performance in a model of early Parkinsonism.
Topics: Adrenergic alpha-Agonists; Analysis of Variance; Animals; Attention; Clonidine; Cognition Disorders; | 2010 |
Growth-hormone release to clonidine and the clinical response to levodopa in parkinsonism.
Topics: Aged; Antiparkinson Agents; Benserazide; Clonidine; Female; Growth Hormone; Humans; Levodopa; Male; | 2002 |
An antihypokinesic action of alpha2-adrenoceptors upon MPTP-induced behaviour deficits in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Clonidine; Dopamine; Dopamine Agonists; Drug I | 2003 |
Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Clonidine; Drug Administration Schedule; Hu | 2003 |